Zymeworks Inc. (NASDAQ: ZYME)

Zymeworks Inc. is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel multifunctional biotherapeutics to improve the standard of care for difficult to treat conditions including cancer, inflammation, and autoimmune disease. The company employs an asset and royalty aggregation strategy to optimize future milestone and royalty cash flows while retaining flexibility to return capital to stockholders. ZW191 targets folate receptor alpha for ovarian, endometrial, and non small cell lung cancer. ZW251 targets glypican 3 for hepatocellular carcinoma. ZW220 targets NaPi2b for non small cell lung cancer, and ovarian cancer. Preclinical programs feature ZW209 a trispecific T cell engager targeting DLL3. ZW1528 is a bispecific antibody targeting IL 4Rα, and IL 33 for autoimmune and inflammatory diseases. Zymeworks relies on its proprietary Azymetric platform for multispecific antibodies, its EFECT platform for Fc modulation, and its drug conjugate platforms for toxin delivery to build these candidates. These platforms enable the design of bispecific and trispecific molecules that can engage multiple targets simultaneously.

Zymeworks generates revenue primarily through upfront payments, milestone payments, and tiered royalties from its collaboration and licensing agreements with pharmaceutical partners. As of December 31, 2025, the company had received $491 million in upfront and milestone payments from Jazz and BeOne related to zanidatamab. Under the Jazz collaboration, Zymeworks is eligible for tiered royalties of 10 to high teens % on global net sales outside Asia, excluding Japan, Australia, and New Zealand, up to $2 billion, and 20% on sales above $2 billion. Under the BeOne collaboration, tiered royalties range from mid single to mid double digit % on annual net sales in Asia, excluding Japan, Australia, and New Zealand, up to $1 billion, and 19.5% on sales above $1 billion. Platform partnerships with BMS, GSK, Daiichi Sankyo, J&J, and Merck have contributed $233.4 million in upfront and milestone payments as of the same date. The Royalty Pharma loan arrangement provided $250 million in upfront cash in exchange for a portion of future Ziihera royalties. These payments provide non dilutive funding that supports research and development activities while preserving financial flexibility for capital allocation decisions.

Zymeworks occupies a niche in the biotechnology sector as a developer of multispecific antibody and antibody drug conjugate platforms competing with larger firms such as Roche, Novartis, AstraZeneca, and Merck, as well as specialized biotechs like Seagen and MacroGenics. In oncology, the company's HER2 targeted asset Ziihera faces competition from established therapies such as Herceptin, Perjeta, Phesgo, Kadcyla, Tykerb, Nerlynx, Enhertu, Tukysa, Margenza, pyrotinib, disitamab vedotin, anbenitamab, and various biosimilars. For FRα directed programs, Zymeworks competes with Elahere and emerging antibody drug conjugates such as Rina S, AZD5335, sofetabart mipitecan, IMGN151, and ABBV901. GPC3 directed candidates are measured against ADCs such as MRG006, BC2027, cell therapies, T cell engagers, radioconjugates, and monoclonal antibodies. IL 4Rα and IL 33 targeted molecules compete with bispecific therapies such as AK139, and other IL 4Ra ST2 bispecifics. Zymeworks' advantages derive from its proprietary protein engineering capabilities, its integrated drug development engine, and its ability to generate non dilutive funding through royalty partnerships. The company's intellectual property portfolio includes more than 300 issued patents covering its therapeutic antibody product candidates and platform technologies.

The company's customer base consists of pharmaceutical and biotechnology partners that license its platforms and product candidates including Jazz Pharmaceuticals, BeOne Medicines Ltd., Bristol Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Johnson & Johnson, and Merck. Jazz Pharmaceuticals holds worldwide rights for zanidatamab, excluding Asia Pacific territories, and leads development and commercialization of the product in those regions. BeOne Medicines Ltd. possesses exclusive rights for zanidatamab in Asia, excluding Japan, as well as in Australia and New Zealand. Bristol Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Johnson & Johnson, and Merck have licensed various of Zymeworks antibody drug conjugate multispecific and Fc engineering platforms for their own research and development programs. These partnerships have generated significant upfront milestone and royalty payments, and provide Zymeworks with access to external funding and expertise.